Study of Vacc-4x Combined with Celgene`s Revlimid® Approved to Begin

Oslo 13.08.2012 – Study of Vacc-4x Combined with Celgene`s Revlimid® (lenalidomide) in HIV Patients with Impaired Immune System Approved to Begin News Summary  Placebo-controlled, double-blind clinical study combining Vacc-4x with Celgene`s Revlimid® (lenalidomide) approved to start at four clinics in Germany  Study seeks to improve the immunological response in patients who have failed to recover …

Read more

Vacc-4x Improves Quality of Immune Responses in HIV Patients, Resulting in Long-Term Reduction in Viral Load

Oslo 20.07.2012 – Therapeutic HIV Vaccine Vacc-4x Improves Quality of Immune Responses in HIV Patients, Resulting in Long-Term Reduction in Viral Load and Potential for Periodic “Boosts” that Could Result in New Treatment Option for People Living with HIV/AIDS. Bionor researchers report findings at AIDS 2012 “Towards an HIV Cure” pre-conference symposium. News summary  • Bionor …

Read more

HIV- and Oncology Research Expert Professor Gus Dalgleish Joins Clinical Advisory Board Bionor Pharma

Oslo, 17.07.2012. HIV- and Oncology Research Expert Professor Gus Dalgleish Joins Clinical Advisory Board Bionor Pharma. Professor Dalgleish joins growing global board to help find a cure or functional cure for HIV Bionor Pharma ASA announced today that the HIV expert from the UK based St. George’s University of London, Professor Angus “Gus” Dalgleish is …

Read more